The synthesis of a series of 4-(7,7-dimethyl-4-[4-{N-aroyl/(het)aroyl/ benzyl}1-piperazinyl]-5,6,7,8-tetrahydroquinazolin-2-yl)morpholine derivatives has been described. The antiviral activity of these compounds against avian paramyxovirus (APMV-1), which is a Newcastle disease virus has also been screened.
Introduction
Heterocyclic chemistry is one of the largest classical divisions within organic chemistry, [1] [2] [3] and its importance is highlighted by the frequency that heterocycles appear in biologically active compounds. Pyrimidines are well known heterocycles which appear in many natural products and are often key starting materials used in many drug discovery projects. [4] [5] [6] A review of literature revealed that substituted pyrimidines have been used to synthesize a variety of protein kinase inhibitors (e.g., JAK, MAP kinase, tyrosine kinases and VEGF receptor) which are being employed in the treatment of a wide range of diseases such as cancers, inflammatory bowel disease and ocular neovascular diseases. [7] [8] 2-Morphilino-substituted pyrimidine derivatives have been used to treat diseases and disorders arising from abnormal cellgrowth, particularly which are associated with PI3 kinase such as cancer, immune disorders, viral infection and neurological disorders. [9] [10] [11] Piperazine is also an important heterocyclic compound present in many of the notable anti-helmintic, anti-depressant and antihistamines drugs.
Results and Discussion
The synthesis of 4-(7,7-dimethyl-4-{piperazin-1-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)morpholine (1) is described in Scheme 1. Commercially available 3,3-dimethyl cyclohexanone (6) on treatment with dimethyl carbonate in the presence of sodium hydride in THF gave methyl 4,4-dimethyl-2-oxocyclohexane-1-carboxylate (5) . 20, 21 The intermediate 5 undergoes cyclization with S-methylisothiourea hemisulfate in water to provide 7,7-dimethyl-2-(methylthio)-5,6,7,8-tetrahydroquinazolin-4(3H)-one (6) . 8 7,7-Dimethyl-2-morpholino-5,6,7,8-tetrahydroquinazolin-4(3H)-one (7) was synthesized from 6 by replacing the SMe group with morpholine. 22 The synthesis of scaffold 4-(7,7-dimethyl-4-{piperazin-1-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)morpholine (1) from 7 involves two nucleophilic replacement reactions, viz. initial replacement of hydroxy group by chloride group in the presence of POCl3 to provide compound 8 and then replacement of chloride group with piperazine (Scheme 1). Scheme 1. Synthesis of 4-(7,7-dimethyl-4-{piperazin-1-yl}-5,6,7,8-tetrahydroquinazolin-2-yl)morpholine (1).
The protocol employed for the synthesis of N-aroyl 2a-g and N-benzyl-substituted piperizine 3a-f derivatives of 1 is depicted in Scheme 2. Several N-aroyl-substituted piperizine derivatives 2a-g were prepared by treating 1 with corresponding substituted benzoyl chloride or heterocyclic acyl chloride a-g. Similarly Nbenzyl-substituted piperizine 3a-f derivatives of 1 were synthesized via reductive amination of 1 by respective aryl aldehydes using sodium triacetoxyborohydride (STAB). The structures of these compounds 2a-g and 3a-f were confirmed by 1 H and 13 C NMR and LCMS spectra. The results provided in the Table 1 indicated that the test compounds 2a and 2c-g showed antiviral activity by inhibiting the plaque formation by 22, 6, 25, 12, 28 and 17%, respectively at the minimum test dose when compared to infected untreated controls, while the compounds 2b and 3a-f did not show any antiviral activity at the tested concentrations. Also, the results suggested that N-aroyl/(het)aroyl derivatives showed antiviral activity, whereas N-benzyl analogues showed no such activity. It is evidently observed that presence of carbonyl group in N-aroyl/(het)aroyl derivatives may be responsible for the antiviral efficacy of these compounds. Among the compounds under investigation N-imidazolyl-substituted piperizine derivative 2f exhibited relatively a higher antiviral activity than the others.
Conclusions
In conclusion, we have reported the novel synthesis of a series of seven 4-(7,7-dimethyl-4-[4-{N-aroyl/(het)aroyl}-substituted 1-piperazinyl]-5,6,7,8-tetrahydroquinazolin-2-yl)morpholine derivatives 2a-g and six 4-(7,7-dimethyl-4-[4-{N-benzyl}-substituted 1-piperazinyl]-5,6,7,8-tetrahydroquinazolin-2-yl)morpholine derivatives 3a-f. Amongst, compounds 2d and 2f which had N-aroyl/(het)aroyl-substituted 1-piperazinyl scaffold showed antiviral activity against APMV-1, a Newcastle disease virus almost equal to marketed drug Ribavirin and further modification of this scaffold or N-aroyl/(het)aroyl substrate would definitely pose lead molecule towards antiviral therapeutics.
Experimental Section
General. All the chemicals used in the study are commercially available high purity grade (Aldrich or Merck, India). Commercially available reagent grade solvents were used as received. TLC experiments were performed on alumina-backed silica gel 40F254 plates (Merck, Germany). The plates were illuminated under UV (254 nm) and KMnO4. Melting points were determined using a melting point apparatus (B-540 Buchi, Germany) without corrections. All 1 H and 13 C NMR spectra were recorded on a Bruker 300 or 400 MHz instrument. Molecular masses of unknown compounds were checked by LCMS 6200 series Agilent Technology instrument. Chemical shifts are reported in ppm (δ) with reference to internal standard TMS. The signals are designated as follows: singlet (s), doublet (d), triplet (t), doublet of doublet (dd), doublet of triplet (dt), multiplet (m), and broad singlet (bs). IR spectra were recorded using a FT-IR spectrometer (Bruker, Germany) using a diamond attenuated total reflectance (ATR) single reflectance module (24 scans). All reactions were carried out under a nitrogen / argon atmosphere unless otherwise stated. Elemental analysis was carried out with a Thermo Scientific, model Flash 1112EA apparatus and Eagar xperience software.
Methyl 4,4-dimethyl-2-oxocyclohexane-1-carboxylate (5).
Dimethyl carbonate (3.3 mL, 0.039 mol) and NaH (1.24 g, 0.052 mol) in THF (24 mL) were heated to about 80°C for 30 min. Then 3,3-dimethyl cyclohexanone (2.0 g, 0.016 mol) was added and stirred for 2.5 h under nitrogen atmosphere. After reactioncompletion by TLC (10% methanol in chloroform), the reaction mass was cooled to about 0°C and methanol followed by water was added. Then the resultant reaction mixture was acidified to pH 1 using 3M HCl and the product was extracted with dichloromethane, dried over sodiumsulphate and concentrated under reduced pressure to afford methyl 4,4-dimethyl-2-oxocyclohexane-1-carboxylate (5). Yield: 2.48 g ; 85%, Pale yellow liquid. 
General procedure for synthesis of 2a-g
To a solution of 1 (0.001 mol) in dichloromethane (10 fold), triethyl amine (0.003 mol) was added slowly under stirring at about 10 o C. To this, corresponding benzoyl chloride a-g (0.0011 mol) was added and stirred for 60 min. Reaction completion was monitored by TLC. After completion, the reaction was quenched with 10% sodium bicarbonate solution and extracted with dichloromethane. Organic layer was washed with 10% of citric acid solution followed by brine solution. Organic layer was concentrated under reduce pressure and purified using column chromatography using ethyl acetate-hexanes to afford pure compounds 2a-g. 4-{7,7-Dimethyl-2-morpholino-5,6,7,8-tetrahydroquinazolin-4-yl}piperazin-1-yl) (4-{7,7-Dimethyl-2-morpholino-5,6,7,8-tetrahydroquinazolin-4-yl}piperazin-1-yl) 4-{7,7-Dimethyl-2-morpholino-5,6,7,8-tetrahydroquinazolin-4-yl}piperazin-1-yl)[1H-imidazol-1 63 (s, 4H), 3.72-3.75 (m, 8H) , 6 .39 (bs, NH), 7-7.39 (m,5H); 13 C NMR (75 MHz, DMSOd6) δ: 22.2, 28.4, 29.3, 44.4, 46.0, 46.5, 47.6, 66.5, 106.3, 119.1, 129.3, 137.6, 150.8,  159.4, 165.3 To the resultant mixture, sodium triacetoxy borohydride (0.0025 mol) was added in several lots and contents were stirred for 4 h to go for completion. After reaction completion by TLC, reaction was quenched with 10% sodium bicarbonate solution and product was extracted using ethyl acetate. Organic layer was dried over sodium sulfate and concentrated to get crude material which was further purified using column chromatography. 4-(4-[4-{4-Bromo-2-fluorobenzyl}piperazin-1-yl]-7,7-dimethyl-5,6,7,8 4-(4-[4-{2-Chloro-3,6-difluorobenzyl}piperazin-1-yl]-7,7-dimethyl-5,6,7,8-tetrahydroquinazolin-2-yl) 
4-(4-[4-{2-

